economic evaluation [ocac]
irbesartan [orch, phsu]
Combination [qlco]
Hydrochlorothiazide [orch, phsu]
treatment [ftcn]
Hypertension [dsyn]
Greece [geoa]
Hypertension [dsyn]
Major [qlco]
Risk factor [qnco]
Cardiovascular disease [dsyn]
Leading [tmco]
Morbidity [qnco]
Mortality [qnco]
This [euka]
Study [mnob]
Evaluate [ftcn]
irbesartan [orch, phsu]
Alternative Therapies [topp]
Hypertension [dsyn]
Losartan [orch, phsu]
valsartan [orch, phsu]
GIVEN [cnce]
Combination [qlco]
Hydrochlorothiazide [orch, phsu]
General Population [popg]
hypertensive [fndg]
Greece [geoa]
Model [inpr]
Eight [qnco]
Health [idcn]
Construct [clas]
Hypertension [dsyn]
Myocardial Infarction [dsyn]
Post [tmco]
Myocardial Infarction [dsyn]
Angina [sosy]
Stroke [dsyn]
Heart failure [dsyn]
Death [orgf]
Model [inpr]
Annual [tmco]
Cycle [tmco]
Estimate [qnco]
Mean [qnco]
Quality [qlco]
Adjusted [ftcn]
Survival [acty]
Treatment Cost [qnco]
reflect [menp]
hypertension treatment [hlca]
Managing [ocac]
cardiovascular events [fndg]
Risk [qlco]
Functions [ftcn]
To [qlco]
Conduct [inbe]
Data [idcn]
Treatment Effectiveness [qlco]
Quality of life [idcn]
Epidemiology [bmod]
Obtained [ftcn]
Published [ocac]
Clinical Trials [resa]
studies [lbpr]
Database [inpr]
Main [qlco]
Greek [popg]
national [inpr]
Social Insurance [gora]
institute [orgt]
Analyzed [resa]
To [qlco]
Estimate [qnco]
Cost [qnco]
Events [evnt]
Analysis [lbpr]
payor [inpr]
Outcome [ftcn]
discount [inpr]
Prices [qnco]
Estimated [qnco]
Cost [qnco]
Per Annum [tmco]
Stable angina [dsyn]
Not [ftcn]
Angina, Unstable [dsyn]
Not [ftcn]
Myocardial Infarction [dsyn]
Not [ftcn]
Post [tmco]
Myocardial Infarction [dsyn]
Not [ftcn]
Stroke [dsyn]
Not [ftcn]
Not [ftcn]
Heart failure [dsyn]
Not [ftcn]
Coronary angiography [diap]
Not [ftcn]
Percutaneous Transluminal Coronary Angioplasty [topp]
Not [ftcn]
Coronary Artery Bypass Graft Surgery [topp]
Not [ftcn]
baseline [bodm]
Group [idcn]
Age-Years [tmco]
Systolic blood pressure [clna]
mmHg [qnco]
Cholesterol [bacs, strd]
mmol/L [qnco]
Body Mass Index [diap]
Men [popg]
Mild to moderate [qlco]
Hypertension [dsyn]
irbesartan [orch, phsu]
Treatment Cost [qnco]
Not [ftcn]
Losartan [orch, phsu]
Not [ftcn]
valsartan [orch, phsu]
Not [ftcn]
Quality-Adjusted Life Years [tmco]
irbesartan [orch, phsu]
Losartan [orch, phsu]
valsartan [orch, phsu]
baseline [bodm]
Group [idcn]
Women [popg]
Mild to moderate [qlco]
Hypertension [dsyn]
Treatment Cost [qnco]
Not [ftcn]
irbesartan [orch, phsu]
Not [ftcn]
Losartan [orch, phsu]
Not [ftcn]
valsartan [orch, phsu]
Quality-Adjusted Life Years [tmco]
irbesartan [orch, phsu]
Losartan [orch, phsu]
valsartan [orch, phsu]
Men [popg]
Severe [qlco]
Hypertension [dsyn]
irbesartan [orch, phsu]
Losartan [orch, phsu]
Treatment Cost [qnco]
Not [ftcn]
Not [ftcn]
Quality-Adjusted Life Years [tmco]
Women [popg]
Treatment Cost [qnco]
Not [ftcn]
Not [ftcn]
Quality-Adjusted Life Years [tmco]
Similar [qlco]
Result [ftcn]
Obtained [ftcn]
treatment [ftcn]
Group [idcn]
Various [irda]
Sensitivity [qnco]
Analysis [lbpr]
scenarios [ftcn]
Based [ftcn]
Efficacy [qlco]
Data [idcn]
Clinical Trials [resa]
Lower [spco]
Cost [qnco]
Various [irda]
hypertensive [fndg]
Population [qnco]
irbesartan [orch, phsu]
Combination [qlco]
Hydrochlorothiazide [orch, phsu]
Compare [acty]
Losartan [orch, phsu]
valsartan [orch, phsu]
Combination [qlco]
Hydrochlorothiazide [orch, phsu]
Greek [popg]
setting [ftcn]
